The European Commission’s Pharmaceutical Sector Inquiry raised significant concerns regarding so-called “reverse payment” patent settlement agreements. In this article, CRA describes the types of information or economic evidence that might facilitate evaluation of the competitive aspects of these settlements. To read the article, click here:
Antitrust in the Middle East: New competition laws, and time for more economics?
In the Middle East, competition law is being increasingly enforced and new laws introduced. However, little has been said about how, if at all the role...